AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11872684 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 19
Study 10453833 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancy (third trimester)
Number of subjects: 48
Study 10453833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclampsia
Number of subjects: 48
Study 10453833 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (pre-eclamptic, normal pregnant, nonpregnant)
Number of subjects: 48
Study 7788682 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate (ACE inhibitor) for six weeks
Number of subjects: 30
Study 2347046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential alternating drug regimen consisting of Adriamycin-cisplatin + vincristine-cyclophosphamide + high-dose methotrexate
Number of subjects: 200
Study 2347046 — intervention group
Group type: COMPARATOR
Intervention: Combination of Adriamycin-cyclophosphamide
Number of subjects: 200
Study 2347046 — intervention group
Group type: COMPARATOR
Intervention: Combination of Adriamycin-cisplatin
Number of subjects: 200
Study 2347046 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosed ifosfamide (used in pilot studies)
Number of subjects: 200
Study 39012 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazepam
Number of subjects: 60
Study 39012 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 60
Study 39012 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorazepate dipotassium
Number of subjects: 60
Study 39012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 39012 — intervention group
Group type: EXPERIMENTAL
Intervention: All drug groups
Number of subjects: 60
Study 30799269 — intervention group
Group type: EXPERIMENTAL
Intervention: LIA with LB 266 mg/20 mL admixed with bupivacaine HCl 0.5% 20 mL
Number of subjects: 139
Study 28953735 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day
Number of subjects: 94
Study 25849298 — intervention group
Group type: EXPERIMENTAL
Intervention: ENB‐TBNA
Number of subjects: 94
Study 25849298 — intervention group
Group type: COMPARATOR
Intervention: C‐TBNA
Number of subjects: 94
Study 23422155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (10,000 units/kg intravenously before surgical incision and 5,000 units/kg on post-op days 1-3)
Number of subjects: 80
Study 23422155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ulinastatin)
Number of subjects: 80
Study 23422155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 80
Study 23422155 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 20823079 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine bromide (0.4 mg i.m.)
Number of subjects: 20
Study 20823079 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study 19940321 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking program (MI-WP)
Number of subjects: 152
Study 19940321 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity activity program (LI-AP)
Number of subjects: 152
Study 17388713 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/day increased to 20 mg/day after week 4)
Number of subjects: 24
Study 17388713 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after tapering from escitalopram)
Number of subjects: 24
Study 14696230 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiMARK (gadoversetamide injection) administered via power injector
Number of subjects: 144
Study 11177120 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized depression management program including patient education, antidepressant pharmacotherapy, systematic telephone monitoring, and psychiatric consultation.
Number of subjects: 407
Study 11177120 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 407
Study 11177120 — intervention group
Group type: EXPERIMENTAL
Intervention: Total health services costs (including health services and time-in-treatment costs).
Number of subjects: 407
Study 11177120 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient health services costs.
Number of subjects: 407
Study 11177120 — intervention group
Group type: EXPERIMENTAL
Intervention: Health services plus time-in-treatment costs.
Number of subjects: 407
Study 11177120 — intervention group
Group type: EXPERIMENTAL
Intervention: Total health services and time-in-treatment costs.
Number of subjects: 407
Study 9717065 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate retard (400 mg once daily)
Number of subjects: 3122
Study 9717065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3122
Study 8169394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg) single dose
Number of subjects: 53
Study 8169394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg) two consecutive days
Number of subjects: 53
Study 8169394 — intervention group
Group type: COMPARATOR
Intervention: Thiabendazole (50 mg/kg/day) twice daily for 3 consecutive days
Number of subjects: 53
Study 3168573 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol, 5 percent solution
Number of subjects: 6
Study 3168573 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoetharine, 1 percent solution
Number of subjects: 6
Study 3168573 — intervention group
Group type: COMPARATOR
Intervention: Atropine (control)
Number of subjects: 6
Study 29197931 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (thrice weekly sessions of lower-limb aerobic and resistance exercise for 12 weeks)
Number of subjects: 38
Study 29197931 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 38
Study 29197931 — intervention group
Group type: COMPARATOR
Intervention: Control group (lower-limb compression therapy)
Number of subjects: 38
Study 27469583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (1500 mg twice daily for 24 months)
Number of subjects: 142
Study 27469583 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (2.0 mg/kg per day for 12 months followed by placebo for 12 months)
Number of subjects: 142
Study 27469583 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (control)
Number of subjects: 142
Study 27469583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 142
Study 25760509 — intervention group
Group type: EXPERIMENTAL
Intervention: Decortication
Number of subjects: 42
Study 25760509 — intervention group
Group type: COMPARATOR
Intervention: Control (compression plate only)
Number of subjects: 42
Study 25760509 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 23798345 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to diesel exhaust
Number of subjects: 12
Study 23798345 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to polluted air
Number of subjects: 12
Study 20496538 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medroxyprogesterone 500 mg/d, megestrol acetate 320 mg/d, oral supplementation with eicosapentaenoic acid (EPA), L‐carnitine 4 g/d, thalidomide 200 mg/d
Number of subjects: 332
Study 20496538 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone 500 mg/d or megestrol acetate 320 mg/d
Number of subjects: 332
Study 20496538 — intervention group
Group type: COMPARATOR
Intervention: Oral supplementation with eicosapentaenoic acid (EPA)
Number of subjects: 332
Study 20496538 — intervention group
Group type: COMPARATOR
Intervention: L‐carnitine 4 g/d
Number of subjects: 332
Study 20496538 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide 200 mg/d
Number of subjects: 332
Study 18468010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 118
Study 18468010 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg
Number of subjects: 118
Study 18468010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 16176316 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 microg.kg(‐1).min(‐1)
Number of subjects: 22
Study 16176316 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0.025 microg.kg(‐1).min(‐1)
Number of subjects: 22
Study 12445223 — intervention group
Group type: EXPERIMENTAL
Intervention: MEM+ AB+
Number of subjects: 25
Study 12445223 — intervention group
Group type: EXPERIMENTAL
Intervention: MEM+ AB-
Number of subjects: 25
Study 12445223 — intervention group
Group type: EXPERIMENTAL
Intervention: MEM- AB+
Number of subjects: 25
Study 12445223 — intervention group
Group type: COMPARATOR
Intervention: MEM- AB-
Number of subjects: 25
Study 10622383 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion therapy (40 mg/kg, maximum 2 g)
Number of subjects: 20
Study 10622383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 20
Study 7733027 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with high polyunsaturated to saturated fat ratio (P:S = 1.0)
Number of subjects: 6
Study 7733027 — intervention group
Group type: COMPARATOR
Intervention: Diet with low polyunsaturated to saturated fat ratio (P:S = 0.2)
Number of subjects: 6
Study 1696669 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of propranolol
Number of subjects: 16
Study 1696669 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of brefanolol
Number of subjects: 16
Study 1696669 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of brefanolol
Number of subjects: 16
Study 1696669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7025642 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditorally augmented feedback during training exercises (tracing line drawings)
Number of subjects: 59
Study 7025642 — intervention group
Group type: EXPERIMENTAL
Intervention: No auditorally augmented feedback during training exercises (tracing line drawings)
Number of subjects: 59
Study 7025642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training exercises)
Number of subjects: 59
Study 31442599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 31626165 — intervention group
Group type: EXPERIMENTAL
Intervention: Akatinol memantine
Number of subjects: 120
Study 31626165 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized training
Number of subjects: 120
Study 31626165 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 120
Study 31626165 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 25925598 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 291
Study 25925598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 24027370 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow (Group A)
Number of subjects: 148
Study 24027370 — intervention group
Group type: COMPARATOR
Intervention: Non-pulsatile flow (Group B)
Number of subjects: 148
Study 21367954 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 12
Study 19262961 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Memory Clinics (MMC)
Number of subjects: 220
Study 19262961 — intervention group
Group type: COMPARATOR
Intervention: General Practitioners (GP)
Number of subjects: 220
Study 17419685 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE (conjugated equine oestrogen) 0.6 mg/day
Number of subjects: 38
Study 17419685 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA (medroxyprogesterone acetate) 10 mg/day
Number of subjects: 38
Study 17419685 — intervention group
Group type: COMPARATOR
Intervention: CEE (conjugated equine oestrogen) 0.6 mg/day and MPA (medroxyprogesterone acetate) 10 mg/day
Number of subjects: 38
Study 15308069 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 U.kg(‐1).d(‐1) of rhGH treatment on 7‐10 PBD, n=16
Number of subjects: 32
Study 15308069 — intervention group
Group type: COMPARATOR
Intervention: 0.25 U.kg(‐1).d(‐1) of normal saline as control, n=16
Number of subjects: 32
Study 11217907 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (1000 microg day(‐1))
Number of subjects: 19
Study 11217907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11217907 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone
Number of subjects: 19
Study 11069569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ass' milk-based diet
Number of subjects: 21
Study 11069569 — intervention group
Group type: COMPARATOR
Intervention: Casein hydrolysate milk-based diet
Number of subjects: 21
Study 9201522 — intervention group
Group type: EXPERIMENTAL
Intervention: dopexamine 2.0 micrograms/kg per min
Number of subjects: 30
Study 9201522 — intervention group
Group type: COMPARATOR
Intervention: dopamine 2.5 micrograms/kg per min
Number of subjects: 30
Study 9201522 — intervention group
Group type: EXPERIMENTAL
Intervention: dopexamine
Number of subjects: 30
Study 9201522 — intervention group
Group type: COMPARATOR
Intervention: dopamine
Number of subjects: 30
Study 1434911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron, 16 mg three times daily for 4 weeks
Number of subjects: 14
Study 1434911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1434911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 14
Study 2997829 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (average dosage 860 mg/day, average duration 29 days)
Number of subjects: 25
Study 2997829 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 25
Study 29355547 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 5162
Study 29355547 — intervention group
Group type: COMPARATOR
Intervention: No β-blockers
Number of subjects: 5162
Study 26687471 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF+ group (n = 17)
Number of subjects: 35
Study 26687471 — intervention group
Group type: COMPARATOR
Intervention: L-PRF- group (n = 18)
Number of subjects: 35
Study 25098313 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of Burden of COPD (ABC) tool
Number of subjects: 360
Study 25098313 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study 22621795 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Care (EC)
Number of subjects: 201
Study 22621795 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 201
Study 20554983 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI group (coformulated abacavir, zidovudine, and lamivudine)
Number of subjects: 560
Study 20554983 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease‐inhibitor group (lopinavir‐ritonavir plus zidovudine‐lamivudine)
Number of subjects: 560
Study 20554983 — intervention group
Group type: COMPARATOR
Intervention: Observational group (nevirapine plus zidovudine‐lamivudine)
Number of subjects: 560
Study 20554983 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI group
Number of subjects: 560
Study 20554983 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease‐inhibitor group
Number of subjects: 560
Study 20554983 — intervention group
Group type: COMPARATOR
Intervention: Observational group
Number of subjects: 560
Study 20554983 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 560
Study 18612042 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of oral carbohydrate (cal) as orange juice
Number of subjects: 19
Study 18612042 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric control (nocal)
Number of subjects: 19
Study 15983800 — intervention group
Group type: COMPARATOR
Intervention: Tiagabine 4 mg
Number of subjects: 12
Study 15983800 — intervention group
Group type: COMPARATOR
Intervention: Tiagabine 8 mg
Number of subjects: 12
Study 15983800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12358327 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-level noninvasive positive-pressure ventilation (NPPV)
Number of subjects: 20
Study 12358327 — intervention group
Group type: COMPARATOR
Intervention: Placebo NPPV
Number of subjects: 20
Study 12358327 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional medical therapy plus two-level NPPV
Number of subjects: 20
Study 12358327 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy plus placebo NPPV
Number of subjects: 20
Study 10065518 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain (4000 pkat)
Number of subjects: 51
Study 10065518 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain (3000 pkat)
Number of subjects: 51
Study 10065518 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated neighboring discs)
Number of subjects: 51
Study 7726802 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Number of subjects: 34
Study 7726802 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment (rational emotive therapy, social skills training, exposure in vivo)
Number of subjects: 34
Study 7726802 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 34
Study 1963383 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Kidney-tonifying decoction (Liu Wei Di Huang or Jin Gui Shen Qi medicinal decoction)
Number of subjects: 83
Study 1963383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no traditional Chinese decoction)
Number of subjects: 83
Study 31400103 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-based SRH helpline provided by a NGO
Number of subjects: 405
Study 31400103 — intervention group
Group type: COMPARATOR
Intervention: Control area (no intervention)
Number of subjects: 405
Study 29172992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix
Number of subjects: 30
Study 29172992 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardasil
Number of subjects: 30
Study 27284114 — intervention group
Group type: EXPERIMENTAL
Intervention: LixiLan (10 units/5 μg, titrated based on Gla-100 requirement)
Number of subjects: 323
Study 27284114 — intervention group
Group type: COMPARATOR
Intervention: Gla-100 (10 units, titrated)
Number of subjects: 323
Study 27284114 — intervention group
Group type: EXPERIMENTAL
Intervention: LixiLan
Number of subjects: 323
Study 27284114 — intervention group
Group type: COMPARATOR
Intervention: Gla-100
Number of subjects: 323
Study 25304364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling intervention (moderate-intensity, 20 to 50 minutes per session, 3 times a week)
Number of subjects: 90
Study 25304364 — intervention group
Group type: COMPARATOR
Intervention: Attention control (low-intensity stretching)
Number of subjects: 90
Study 22695488 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline for 21 days
Number of subjects: 17
Study 22695488 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 17
Study 19875133 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 123
Study 19875133 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 18519771 — intervention group
Group type: EXPERIMENTAL
Intervention: dMMR/BRAF(-)
Number of subjects: 533
Study 18519771 — intervention group
Group type: EXPERIMENTAL
Intervention: dMMR
Number of subjects: 533
Study 18519771 — intervention group
Group type: COMPARATOR
Intervention: BRAF V600E mutation status
Number of subjects: 533
Study 18519771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of dMMR tumors
Number of subjects: 533
Study 16200539 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist) at 0.1 mmol/kg
Number of subjects: 16
Study 16200539 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist) at 0.2 mmol/kg
Number of subjects: 16
Study 16200539 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate-dimeglumine (MultiHance) at 0.1 mmol/kg
Number of subjects: 16
Study 16200539 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate-dimeglumine (MultiHance) at 0.2 mmol/kg
Number of subjects: 16
Study 12970204 — intervention group
Group type: EXPERIMENTAL
Intervention: Full arterial revascularization (FAR)
Number of subjects: 200
Study 12970204 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting (CABG)
Number of subjects: 200
Study 10664331 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation with oral antibiotics (kanamycin and metronidazole three times on the day before surgery)
Number of subjects: 83
Study 10664331 — intervention group
Group type: COMPARATOR
Intervention: Mechanical preparation alone (group 1)
Number of subjects: 83
Study 10664331 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation with oral antibiotics (group 2)
Number of subjects: 83
Study 8858230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal insertion of thin video endoscope
Number of subjects: 10
Study 8858230 — intervention group
Group type: COMPARATOR
Intervention: Oral insertion of thin video endoscope
Number of subjects: 10
Study 1623912 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (850 mg) with tolbutamide (500 mg)
Number of subjects: 32
Study 1623912 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (850 mg) with chlorpropamide (250 mg)
Number of subjects: 32
Study 1623912 — intervention group
Group type: COMPARATOR
Intervention: Tolbutamide (500 mg) without magnesium hydroxide
Number of subjects: 32
Study 1623912 — intervention group
Group type: COMPARATOR
Intervention: Chlorpropamide (250 mg) without magnesium hydroxide
Number of subjects: 32
Study 6147837 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 12
Study 6147837 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam
Number of subjects: 12
Study 6147837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30244026 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based model for estimating breath alcohol concentration (BrAC) from transdermal alcohol concentration (TAC) data.
Number of subjects: 0
Study 30244026 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-simulated TAC curve and breath analyzer BrAC data comparison.
Number of subjects: 0
Study 30244026 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent of raw BrAC captured within the eBrAC curve credible bands.
Number of subjects: 0